Abstract

Human induced pluripotent stem cells (iPSCs) are a valuable tool for studying the cardiac developmental process in vitro, and cardiomyocytes derived from iPSCs are a putative cell source for personalized medicine. Changes in mitochondrial morphology have been shown to occur during cellular reprogramming and pluripotent stem cell differentiation. However, the relationships between mitochondrial dynamics and cardiac mesoderm commitment of iPSCs remain unclear. Here we demonstrate that changes in mitochondrial morphology from a small granular fragmented phenotype in pluripotent stem cells to a filamentous reticular elongated network in differentiated cardiomyocytes are required for cardiac mesodermal differentiation. Genetic and pharmacological inhibition of the mitochondrial fission protein, Drp1, by either small interfering RNA or Mdivi-1, respectively, increased cardiac mesoderm gene expression in iPSCs. Treatment of iPSCs with Mdivi-1 during embryoid body formation significantly increased the percentage of beating embryoid bodies and expression of cardiac-specific genes. Furthermore, Drp1 gene silencing was accompanied by increased mitochondrial respiration and decreased aerobic glycolysis. Our findings demonstrate that shifting the balance of mitochondrial morphology toward fusion by inhibition of Drp1 promoted cardiac differentiation of human iPSCs with a metabolic shift from glycolysis towards oxidative phosphorylation. These findings suggest that Drp1 may represent a new molecular target for future development of strategies to promote the differentiation of human iPSCs into cardiac lineages for patient-specific cardiac regenerative medicine.

Highlights

  • Cardiomyocytes derived from iPSCs can be used for cell-Induced pluripotent stem cells represent a based therapy to treat heart disease, drug screening and major advance for potential autologous cell therapies. cardiac disease modelling

  • Changes in mitochondrial morphology during cardiac differentiation To investigate the regulation of mitochondrial morphology during cardiac differentiation of human iPSCs, the morphology of mitochondria and expression of genes related to mitochondrial morphology were compared between undifferentiated iPSCs and derived cardiomyocytes

  • In CERA007c6 iPSCs, the mRNA expression of MFN2 was similar between undifferentiated iPSCs and the derived cardiomyocytes while the mRNA expression of MFN1 was significantly lower in the derived cardiomyocytes (Supplemental Figure S1A)

Read more

Summary

Introduction

Cardiomyocytes derived from iPSCs can be used for cell-Induced pluripotent stem cells (iPSCs) represent a based therapy to treat heart disease, drug screening and major advance for potential autologous cell therapies. cardiac disease modelling. Cardiomyocytes derived from iPSCs can be used for cell-. Induced pluripotent stem cells (iPSCs) represent a based therapy to treat heart disease, drug screening and major advance for potential autologous cell therapies. Several agents have been shown to promote differentiation of pluripotent stem cells. Full list of author information is available at the end of the article toward cardiomyogenic lineages, mainly through manipulation of the transforming growth factor-β (TGF-β), Nodal, Wnt, Notch and fibroblast growth factor signalling pathways[1,2]. These authors contributed : Ashfaqul Hoque, Priyadharshini Sivakumaran, Simon T. Official journal of the Cell Death Differentiation Association

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call